IP Library Granted Patent US 9,867,824
Granted Patent B2
US 9,867,824 · App. 15/192,491 · Granted Jan 16, 2018

Heterocyclic compounds and uses thereof

Inventors: Kwangho Lee (Daejeon, KR); Deqiang Niu (Lexington, MA); Russell C. Petter (Stow, MA); Matthew Frank Baevsky (Northborough, MA); Juswinder Singh (Southborough, MA)
Assignee: Celgene CAR LLC
A61K31/506A61K31/5377A61K31/541A61K31/551C07D239/34C07D239/42C07D239/47C07D239/48C07D403/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,867,824
App. No.
15/192,491
Granted
Jan 16, 2018
Kind
B2
Abstract

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Claims (39)

1. A method for treating a proliferative disorder comprising administering to a patient in need thereof a compound represented by structural formula I-a

or a pharmaceutically acceptable salt thereof, wherein:

n is 0, 1, or 2;

m is 0, 1, or 2, wherein m and n are not simultaneously 0;

W is —O— or —NH—;

R 1 is —OR;

each R is independently C 1-4 alkyl or C 1-4 fluoroalkyl;

R 2 is —CF 3 , Cl, or Br;

G is —NR 3 — or —S(O) 2 —; and

R 3 is —C(O)—R, —C(O)OR, —C(O)NHR, —SO 2 —R, —SO 2 NH 2 , —C(O)—C 1-4 alkylene-OH or —SO 2 —C 1-4 alkylene-OH; and

wherein the proliferative disorder is a cancer.

2. The method of claim 1 , wherein the cancer is selected from: breast cancer, glioblastoma, lung cancer, cancer of the head and neck, colorectal cancer, and bladder cancer.

3. The method of claim 2 , wherein the cancer is a lung cancer.

4. The method of claim 3 , wherein the lung cancer is non-small cell lung cancer.

5. The method of claim 1 , wherein the compound is represented by structural formula III-a:

or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 , wherein W is —NH—.

7. The method of claim 5 , wherein R 2 is —CF 3 .

8. The method of claim 5 , wherein:

R 2 is —CF 3 or Cl; and

R 3 is —C(O)CH 3 or —SO 2 CH 3 .

9. The method of claim 6 , wherein:

R 2 is —CF 3 or Cl; and

R 3 is —C(O)CH 3 .

10. The method of claim 6 , wherein:

R 2 is —CF 3 or Cl; and

R 3 is —SO 2 CH 3 .

11. The method according to claim 5 , wherein:

W is —O—;

R 2 is —CF 3 or Cl; and

R 3 is —C(O)CH 3 .

12. The method of claim 5 , wherein:

W is —O—;

R 2 is —CF 3 or Cl; and

R 3 is —SO 2 CH 3 .

13. The method of claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

14. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

Assignments (3)
NUNC PRO TUNC ASSIGNMENT Recorded May 3, 2023
From: CELGENE CAR LLC
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 063526/0959 →
MERGER AND CHANGE OF NAME Recorded Feb 16, 2017
From: CELGENE AVILOMICS RESEARCH, INC.; CELGENE CAR LLC
To: CELGENE CAR LLC
Reel/Frame 041738/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2016
From: NIU, DEQIANG; PETTER, RUSSELL C.; BAEVSKY, MATTHEW FRANK; LEE, KWANGHO; SINGH, JUSWINDER
To: CELGENE AVILOMICS RESEARCH, INC.
Reel/Frame 040022/0174 →
Continuity (7)
Continuation 14636905 · Mar 3, 2015
Division 13286061 · Oct 31, 2011
Provisional Application 61534323 · Sep 13, 2011
Provisional Application 61412330 · Nov 10, 2010
Provisional Application 61411829 · Nov 9, 2010
Provisional Application 61409080 · Nov 1, 2010
Related Publication 20170027937A1 · Feb 2, 2017